All News
Promising! #Cenerimod is a selective S1P1 Receptor modulator has potential in SLE through modulating lymphocyte trafficking, inflammation, and autoantigen transport. Phase 2 showed reduced T/B lymphocytes, autoAb levels, and secretions of IFN-a. #abstr0584 @rheumNow #ACR23
TheDaoIndex KDAO2011 ( View Tweet)
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Great work by @Yuz6Yusof
ANA positive and diagnosis , prediction tool to rule out/ in autoimmune pathology.
1-High interferon score.
2-FH autoimmune disease.
3- More criteria.
?Monogenic error of immune system , ?genome assessment .
@RheumNow , Daily recap
Nouf Al hemmadi ( View Tweet)
I vote for the ❤️
Several abstracts evaluated cardiovascular event prevalence and screening tools using ECHO, carotid ultrasound as current CV risk calculators are inadequate when assessing SLE CV risk. See my blog - just published @RheumNow
https://t.co/XLc0YHtJ0B https://t.co/oF0fXBRM6O
TheDaoIndex KDAO2011 ( View Tweet)
1-Can we prevent RA ? Vagotomy?
2-CV events in auto immune rheumatic disease pregnancies.
3-CVS vasculitis , challenges and role of Brain biopsy
And others……..
https://t.co/BX8bDSX1M3
@RheumNow , daily recap
#ACR23
Nouf Al hemmadi ( View Tweet)
Sunday recap @RheumNow
Very interesting abstracts:
https://t.co/BX8bDSX1M3
1- Fecal calprotectin in SpA population.
2-SLE; high or low steroids? Rapid or slow taper?
3-Molecular biomarkers for PAH in SLE.
4-Repeating imaging in ? Chronic back pain?
And others …….
Nouf Al hemmadi ( View Tweet)
#ACR23 Abstr#0784 Beyond renal response, let’s also focus on kidney function and Steroid-sparing effect. Post-hoc analysis of Phase 2 RCT showed Obinutuzumab preserved eGFR by 4ml/min/1.73m2/year with greater number of pts achieving <7.5mg/d of prednisolone bs PBO @RheumNowNews https://t.co/2hW74UF1ta
Md Yuzaiful Md Yusof ( View Tweet)
#ACR23 Abstr#0590 Graphical Abstract makes it easy to follow 👏. Data using EHR showed that in #SLE with Diabetes, SGLT2-i vs DPP4-i was associated with reduced risks of developing AKI, CKD, ESRD, hospitalisation, and heart failure. Genital infection is common @RheumNowNews https://t.co/Iku6LqoYVb
Md Yuzaiful Md Yusof ( View Tweet)
Cognitive function in PMR @DrTrishHarkins 71% cognitively impaired! Markedly higher than population level #ACR23 @RheumNow https://t.co/0KTnssktKz https://t.co/XyjFzioiqB
Richard Conway ( View Tweet)
20 years real-world data on disease burden, patient experience & unmet needs in Refractory #RheumatoidArthritis
▶️Higher glucocorticoid & opioid use
▶️Greater comorbidity & symptom burden
▶️More rheumatology visits
#ACR23
👉🏽https://t.co/CAUorjQbvN
by @KristinWipfler @Dr_K et al https://t.co/vx1aOZizfE
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
The Rheum Where It Happened! https://t.co/3gL5RLSNms
TheDaoIndex KDAO2011 ( View Tweet)
#ACR23 Abstr#0571 As there is a genetic predisposition to #SLE, can polygenic risk score distinguish SLE vs ANA+ with no disease? A study in European ancestry showed modest discrimination (AUC: 0.66). This showed other contributors are vital in SLE development @RheumNowNews https://t.co/qiFOlOxq5r
Md Yuzaiful Md Yusof ( View Tweet)
OMG! The #Gerirheum community is looking into this bias— pls fill out their survey @UnaMakris @SattuiSEMD https://t.co/Axaoo3WohH
TheDaoIndex KDAO2011 ( View Tweet)
Stop by the @rheumnow booth next to the ACR hub in the exhibit hall… we have fun trying to keep you current! BTW, watch us on the daily recap at https://t.co/kG93OYaNIx https://t.co/wuPxhyljgP
TheDaoIndex KDAO2011 ( View Tweet)
Automated #deeplearning systems #ArtificialIntelligence identify & predict joint damage in hand radiographs from #RheumatoidArthritis patients
➡️May aid in monitoring joint damage
#ACR23
👉🏽https://t.co/IcoZHY6lns https://t.co/mZWg6YIUp3
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
ABS0433:
⭐️Older adults w/ RA less likely to receive tx w/ DMARDs despite being well tolerated and effective
➡️Retrospect, obs using Medicare data
➡️At least 66 yo old w/ new dx of late-onset RA (LORA)
🚩If no contraindications, start DMARDs early in LORA!
#ACR23 @RheumNow https://t.co/ChalcgtS2O
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Great work @sharoncowley01 https://t.co/llUF6REOFR https://t.co/Ej8fQlTNH0
Barry O'Shea ( View Tweet)
Great talk by @DrPujaMehta1
📦 out of the box!
#ACR23 #ACRambassador
@ACRheum https://t.co/dmr0m6W2ZP
Nelly ZIADE 🍀 Nellziade ( View Tweet)
⭐️Real world data on use of #avacopan presented by @zach_wallace_md
#vasculitis
Important observations to inform the practice and management of #AAV https://t.co/gtZORcnt9t
KenWarringtonMD MdWarrington ( View Tweet)
@gurdeep_dulay I ask the same question always, why would you stop denosumab? Nothing comes close to fully ameliorating the negative consequences of doing so. Denosumab is for life, until we figure out how to safely get off it. Don't start it unless that is acceptable #ACR23
Richard Conway ( View Tweet)